The companies plan to test the safety and effectivness of several combinations from their product lines. Both companies will provide resources, and Lilly researchers will head up the studies. Further details, including the type of tumors to be studied and financial terms, have been kept confidential.
AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), will be combined with Lilly molecules that target the immune system, including TGF-beta kinase inhibitor, galunisertib; CXCR4 peptide antagonist; and an anti-CSF-1R monoclonal antibody.
“The extension of our collaboration with Lilly further supports our combination-focused oncology strategy and adds to our broad development program across small molecules and immunotherapies,” Lilly Oncology Senior Vice President of Product Development and Medical Affairs Richard Gaynor said.
Lilly and AstraZeneca launched a Phase I clinical trial partnership to study combining durvalumab and ramucirumab as a treatment for patients with advanced solid tumors earliwer this year.
Alerts Sign-up